131 related articles for article (PubMed ID: 35793805)
1. PCR-Fluo-ASXL1-FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies.
Friedrich C; Zalmaï L; Gay J; Coude MM; Bravetti C; Vazquez R; Temple M; Duroyon E; Darnige L; Decroocq J; Alary AS; Kosmider O
Int J Lab Hematol; 2022 Oct; 44(5):928-933. PubMed ID: 35793805
[TBL] [Abstract][Full Text] [Related]
2. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
Montes-Moreno S; Routbort MJ; Lohman EJ; Barkoh BA; Kanagal-Shamanna R; Bueso-Ramos CE; Singh RR; Medeiros LJ; Luthra R; Patel KP
PLoS One; 2018; 13(9):e0204218. PubMed ID: 30222780
[TBL] [Abstract][Full Text] [Related]
3. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
4. Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.
Schejbel L; Novotny GW; Breinholt MF; El Fassi D; Schöllkopf C; Hogdall E; Nørgaard P
Mol Diagn Ther; 2021 Mar; 25(2):251-266. PubMed ID: 33687704
[TBL] [Abstract][Full Text] [Related]
5. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract][Full Text] [Related]
6. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
7. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
8. Role of ASXL1 in hematopoiesis and myeloid diseases.
Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
[TBL] [Abstract][Full Text] [Related]
9. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
[No Abstract] [Full Text] [Related]
10. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract][Full Text] [Related]
11. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
Pratcorona M; Abbas S; Sanders MA; Koenders JE; Kavelaars FG; Erpelinck-Verschueren CA; Zeilemakers A; Löwenberg B; Valk PJ
Haematologica; 2012 Mar; 97(3):388-92. PubMed ID: 22058207
[TBL] [Abstract][Full Text] [Related]
12. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.
Chou WC; Huang HH; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Ko BS; Wu SJ; Huang SY; Hsu SC; Chen YC; Huang YN; Chang YC; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2010 Nov; 116(20):4086-94. PubMed ID: 20693432
[TBL] [Abstract][Full Text] [Related]
15. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
16. ASXL1 mutation in clonal hematopoiesis.
Fujino T; Kitamura T
Exp Hematol; 2020 Mar; 83():74-84. PubMed ID: 31945396
[TBL] [Abstract][Full Text] [Related]
17. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
[TBL] [Abstract][Full Text] [Related]
18. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
19. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
[TBL] [Abstract][Full Text] [Related]
20. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]